Neuropace Inc
NASDAQ:NPCE

Watchlist Manager
Neuropace Inc Logo
Neuropace Inc
NASDAQ:NPCE
Watchlist
Price: 11.895 USD -6.04%
Market Cap: 389.6m USD

Wall Street
Price Targets

NPCE Price Targets Summary
Neuropace Inc

Wall Street analysts forecast NPCE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NPCE is 17.194 USD with a low forecast of 14.14 USD and a high forecast of 21 USD.

Lowest
Price Target
14.14 USD
19% Upside
Average
Price Target
17.194 USD
45% Upside
Highest
Price Target
21 USD
77% Upside
Neuropace Inc Competitors:
Price Targets
688236
Beijing Chunlizhengda Medical Instruments Co Ltd
6% Upside
DXR
Daxor Corp
214% Upside
BFLY
Butterfly Network Inc
61% Upside
STXS
Stereotaxis Inc
115% Upside
PRM
Prim SA
58% Upside
AFX
Carl Zeiss Meditec AG
9% Upside
CVRX
CVRx Inc
152% Upside
FPH
Fisher & Paykel Healthcare Corporation Ltd
4% Upside

Revenue
Forecast

Revenue Estimate
Neuropace Inc

For the last 4 years the compound annual growth rate for Neuropace Inc's revenue is 18%. The projected CAGR for the next 3 years is 20%.

18%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Neuropace Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Net Income
Forecast

Net Income Estimate
Neuropace Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-28%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NPCE's stock price target?
Price Target
17.194 USD

According to Wall Street analysts, the average 1-year price target for NPCE is 17.194 USD with a low forecast of 14.14 USD and a high forecast of 21 USD.

What is Neuropace Inc's Revenue forecast?
Projected CAGR
20%

For the last 4 years the compound annual growth rate for Neuropace Inc's revenue is 18%. The projected CAGR for the next 3 years is 20%.

Back to Top